In phase II study, Talzenna shrank tumors in breast cancer patients with PALB2 mutations

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Researchers at UT Southwestern reported in the journal Nature Cancer that Talzenna (talazoparib) successfully shrank the tumors of breast cancer patients with mutations in the PALB2 gene. 

To access this subscriber-only content please log in or renew your subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Login